drugset
drugset / Trial / NCT04535752

A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

NCT04535752 ↗

Phase 1 Completed 48 enrolled Annexon, Inc. Nucleus Network Ltd · collab
RandomizedSequentialDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmakokinetics and pharmacodynamics of single and repeated doses of ANX009

Timeline

Start
2020-10-30
Primary completion
2021-06-26
Completion
2021-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject ANX009 Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.